At present three erythropoietic-stimulating agents (ESAs) are available, these being epoietin alpha, epoietin beta and darbepoietin. In oncology the marketing licence given in the early 1990s was and still is for reduction of red blood cell (RBC) transfusion in chemotherapy-induced anaemia (CIA) in non-haematological neoplasia. Regulatory bodies as well as various scientific societies have issu...

Element Stewardship Abstracts (ESAs) are prepared to provide The Nature Conservancy's Stewardship staff and other land managers with current management-related information on those species and communities that are most important to protect, or most important to control. The abstracts organize and summarize data from numerous sources including literature and researchers and managers actively wor...

Element Stewardship Abstracts (ESAs) are prepared to provide The Nature Conservancy's Stewardship staff and other land managers with current management-related information on those species and communities that are most important to protect, or most important to control. The abstracts organize and summarize data from numerous sources including literature and researchers and managers actively wor...

INTRODUCTION Randomized controlled trials (rcts) are the "gold standard" for establishing treatment efficacy; however, efficacy does not automatically translate to a comparable level of effectiveness in routine practice. Our objectives were to □ describe outcomes of palliative platinum-doublet chemotherapy (ppdc) in non-small-cell lung cancer (nsclc) in routine practice, in terms of survival an...

Renal anemia is a complication of chronic kidney disease. Guidelines for safe and effective treatment in patients with renal anemia are needed. The Japanese Society for Dialysis Therapy (JSDT) published guidelines for the treatment of renal anemia in chronic hemodialysis patients in 2004 and in hemodialysis, peritoneal dialysis, predialysis, and pediatric patients in 2008. These two publication...

BACKGROUND Patients with end-stage renal disease (ESRD) require phosphate binders for hyperphosphatemia and erythropoiesis-stimulating agents (ESAs) and intravenous (i.v.) iron for anemia. Ferric citrate (FC) is a novel, iron-based phosphate binder that increases iron stores and decreases i.v. iron and ESA usage while maintaining hemoglobin levels, and may decrease the cost of ESRD care. The st...

The treatment of renal anaemia in patients with chronic kidney disease (CKD) has always been a challenge. The introduction of erythropoiesis-stimulating agents (ESAs) appeared to be a milestone, enabling physicians to avoid red blood cell transfusions in this patient group. In the last decade, however, these assumed advances were tarnished by the occurrence of a new condition: ESA-induced, anti...